243 related articles for article (PubMed ID: 26692336)
21. Population-Level Herd Protection of Males From a Female Human Papillomavirus Vaccination Program: Evidence from Australian Serosurveillance.
Pillsbury AJ; Quinn HE; Evans TD; McIntyre PB; Brotherton JML
Clin Infect Dis; 2017 Sep; 65(5):827-832. PubMed ID: 29017279
[TBL] [Abstract][Full Text] [Related]
22. Assessing genital human papillomavirus genoprevalence in young Australian women following the introduction of a national vaccination program.
Osborne SL; Tabrizi SN; Brotherton JM; Cornall AM; Wark JD; Wrede CD; Jayasinghe Y; Gertig DM; Pitts MK; Garland SM;
Vaccine; 2015 Jan; 33(1):201-8. PubMed ID: 25444787
[TBL] [Abstract][Full Text] [Related]
23. Decline in prevalence of human papillomavirus infection following vaccination among Australian Indigenous women, a population at higher risk of cervical cancer: The VIP-I study.
McGregor S; Saulo D; Brotherton JML; Liu B; Phillips S; Skinner SR; Luey M; Oliver L; Stewart M; Tabrizi SN; Garland S; Kaldor JM
Vaccine; 2018 Jul; 36(29):4311-4316. PubMed ID: 29880245
[TBL] [Abstract][Full Text] [Related]
24. Estimation of HPV prevalence in young women in Scotland; monitoring of future vaccine impact.
Kavanagh K; Sinka K; Cuschieri K; Love J; Potts A; Pollock KG; Cubie H; Donaghy M; Robertson C
BMC Infect Dis; 2013 Nov; 13():519. PubMed ID: 24188790
[TBL] [Abstract][Full Text] [Related]
25. Impact of partial bivalent HPV vaccination on vaccine-type infection: a population-based analysis.
Cuschieri K; Kavanagh K; Moore C; Bhatia R; Love J; Pollock KG
Br J Cancer; 2016 May; 114(11):1261-4. PubMed ID: 27115467
[TBL] [Abstract][Full Text] [Related]
26. Would young women attending sexually transmitted disease clinics benefit from human papillomavirus vaccination? An assessment of human papillomavirus DNA and seropositivity from human papillomavirus sentinel surveillance, 2003-2005.
Dunne EF; Flagg EW; Unger ER; Hsu K; Ghanen K; Kerndt P; Shlay JC; Koutsky LA; Datta DS; Panicker G; Zaidi A; Weinstock H; Markowitz LE
Sex Transm Dis; 2014 Jan; 41(1):46-9. PubMed ID: 24326582
[TBL] [Abstract][Full Text] [Related]
27. Mothers' acceptance of human papillomavirus (HPV) vaccination for daughters in a country with a high prevalence of HPV.
Alder S; Gustafsson S; Perinetti C; Mints M; Sundström K; Andersson S
Oncol Rep; 2015 May; 33(5):2521-8. PubMed ID: 25738832
[TBL] [Abstract][Full Text] [Related]
28. Long-term impact of human papillomavirus vaccination on infection rates, cervical abnormalities, and cancer incidence.
Bogaards JA; Coupé VM; Xiridou M; Meijer CJ; Wallinga J; Berkhof J
Epidemiology; 2011 Jul; 22(4):505-15. PubMed ID: 21540743
[TBL] [Abstract][Full Text] [Related]
29. Assessing the cost-effectiveness of HPV vaccination strategies for adolescent girls and boys in the UK.
Datta S; Pink J; Medley GF; Petrou S; Staniszewska S; Underwood M; Sonnenberg P; Keeling MJ
BMC Infect Dis; 2019 Jun; 19(1):552. PubMed ID: 31234784
[TBL] [Abstract][Full Text] [Related]
30. Low prevalence of vaccine-type HPV infections in young women following the implementation of a school-based and catch-up vaccination in Quebec, Canada.
Goggin P; Sauvageau C; Gilca V; Defay F; Lambert G; Mathieu-C S; Guenoun J; Comète E; Coutlée F
Hum Vaccin Immunother; 2018 Jan; 14(1):118-123. PubMed ID: 29049007
[TBL] [Abstract][Full Text] [Related]
31. The Impact of the National HPV Vaccination Program in England Using the Bivalent HPV Vaccine: Surveillance of Type-Specific HPV in Young Females, 2010-2016.
Mesher D; Panwar K; Thomas SL; Edmundson C; Choi YH; Beddows S; Soldan K
J Infect Dis; 2018 Aug; 218(6):911-921. PubMed ID: 29917082
[TBL] [Abstract][Full Text] [Related]
32. Human papillomavirus prevalence and type-distribution, cervical cancer screening practices and current status of vaccination implementation in Russian Federation, the Western countries of the former Soviet Union, Caucasus region and Central Asia.
Rogovskaya SI; Shabalova IP; Mikheeva IV; Minkina GN; Podzolkova NM; Shipulina OY; Sultanov SN; Kosenko IA; Brotons M; Buttmann N; Dartell M; Arbyn M; Syrjänen S; Poljak M
Vaccine; 2013 Dec; 31 Suppl 7():H46-58. PubMed ID: 24332297
[TBL] [Abstract][Full Text] [Related]
33. Prevalence of Human Papillomavirus and Estimation of Human Papillomavirus Vaccine Effectiveness in Thimphu, Bhutan, in 2011-2012 and 2018 : A Cross-sectional Study.
Baussano I; Tshomo U; Tenet V; Heideman DAM; Wangden T; Franceschi S; Clifford GM
Ann Intern Med; 2020 Dec; 173(11):888-894. PubMed ID: 32956600
[TBL] [Abstract][Full Text] [Related]
34. Postlicensure monitoring of HPV vaccination programmes.
Markowitz LE; Hariri S
Lancet Infect Dis; 2014 Oct; 14(10):904-5. PubMed ID: 25107681
[No Abstract] [Full Text] [Related]
35. Substantial Decline in Vaccine-Type Human Papillomavirus (HPV) Among Vaccinated Young Women During the First 8 Years After HPV Vaccine Introduction in a Community.
Kahn JA; Widdice LE; Ding L; Huang B; Brown DR; Franco EL; Bernstein DI
Clin Infect Dis; 2016 Nov; 63(10):1281-1287. PubMed ID: 27655996
[TBL] [Abstract][Full Text] [Related]
36. On the Elimination of Infections Related to Oncogenic Human Papillomavirus: An Approach Using a Computational Network Model.
Muñoz-Quiles C; Díez-Domingo J; Acedo L; Sánchez-Alonso V; Villanueva RJ
Viruses; 2021 May; 13(5):. PubMed ID: 34068358
[TBL] [Abstract][Full Text] [Related]
37. Decline of HPV infections in Scandinavian cervical screening populations after introduction of HPV vaccination programs.
Dillner J; Nygård M; Munk C; Hortlund M; Hansen BT; Lagheden C; Liaw KL; Kjaer SK
Vaccine; 2018 Jun; 36(26):3820-3829. PubMed ID: 29778519
[TBL] [Abstract][Full Text] [Related]
38. Human Papillomavirus Vaccine Effectiveness and Herd Protection in Young Women.
Spinner C; Ding L; Bernstein DI; Brown DR; Franco EL; Covert C; Kahn JA
Pediatrics; 2019 Feb; 143(2):. PubMed ID: 30670582
[TBL] [Abstract][Full Text] [Related]
39. Geographical disparities in human papillomavirus herd protection.
Berenson AB; Hirth JM; Chang M
Cancer Med; 2020 Jul; 9(14):5272-5280. PubMed ID: 32483924
[TBL] [Abstract][Full Text] [Related]
40. Cost-effectiveness of sex-neutral HPV-vaccination in Sweden, accounting for herd-immunity and sexual behaviour.
Wolff E; Elfström KM; Haugen Cange H; Larsson S; Englund H; Sparén P; Roth A
Vaccine; 2018 Aug; 36(34):5160-5165. PubMed ID: 30017146
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
